INF108

About Infinant Health

Infinant Health is a private, clinical-stage biotech company spun out from the University of California, Davis, focusing on the critical window of infant gut microbiome development. Its lead program, INF108, is a next-generation drug strain of B. infantis designed to prevent necrotizing enterocolitis (NEC) in premature infants, representing a significant unmet medical need. The company also commercializes Evivo, a probiotic supplement for term infants, providing early revenue and real-world evidence. Founded on deep academic research into the interaction between breast milk and the infant microbiome, Infinant aims to restore beneficial bacteria lost in modern populations to build a foundation for lifelong health.

Therapeutic Areas